MedPath

Incidence & assessment of tranexamic acid in reducing postpartum bleeding in pre eclampsia patients undergoing LSCS

Phase 2
Conditions
Health Condition 1: O72- Postpartum hemorrhage
Registration Number
CTRI/2023/10/059089
Lead Sponsor
Command hospital Central Command Lucknow
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Pregnant women with period of gestation 37-42 weeks with documented pre-eclampsia as per ACOG criteria

Exclusion Criteria

moderate anemia (Hb <10 gm%),

Patient on anticoagulation,

Eclampsia,

ASA III & IV

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To evaluate the effects of tranexamic acid on blood loss in patients with pre eclampsia undergoing LSCS <br/ ><br>Timepoint: post-operative period within 48 hours
Secondary Outcome Measures
NameTimeMethod
1. To evaluate the effect of tranexamic acid on the incidence of PPH in patients with pre-eclampsia patients undergoing LSCS. <br/ ><br>2. To evaluate the effect of tranexamic acid on the requirement of blood & blood products in pre-eclampsia patients undergoing LSCS. <br/ ><br>3. To evaluate the effect of tranexamic acid on the Haemoglobin in pre-eclampsia patients undergoing LSCS. <br/ ><br>4. To evaluate the safety of tranexamic acid in patients with pre-eclampsia undergoing LSCS. <br/ ><br>Timepoint: post-operative period within 48 hours
© Copyright 2025. All Rights Reserved by MedPath